Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.

Michel Bolla Anouk Neven Philippe Maingon Christian CarrieAna BoladerasDemetrios AndreopoulosAntoine EngelenSanthanam SundarElzbieta M van der Steen-BanasikJohn ArmstrongKarine Peignaux-CasasnovasJihane BoustaniFernanda G HerreraBradley R PietersAnnerie SlotAmit Bahl Christopher D ScraseDavid AzriaJan JansaJoe M O'SullivanAlphonsus C M Van Den BerghLaurence Collettenull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Six months of concomitant and adjuvant AS statistically significantly improves EFS and DFS in intermediate-risk prostatic carcinoma, treated by irradiation at 74 or 78 Gy. The effects on OS and DMFS did not reach statistical significance.

Keyphrases

prostate cancer
radical prostatectomy
clinical trial
study protocol
randomized controlled trial
phase ii
newly diagnosed